Podcasts about restasis

Dr. Whitley wears many hats as a practicing optometrist at Virginia Eye Consultants, where he also serves as Director of Professional Relations and Education and Regional Medical Director. Since graduating around the same time Restasis hit the market, Dr. Whitley has been at the forefront of recent research and innovation in the diagnosis and treatment of dry eye disease. In fact, he's been involved in more than a dozen clinical trials and enjoys lecturing to share his key learnings. Dr. Whitley shares his dry eye workup including patient assessment and various testing he may or may not do based on symptoms. When treating dry eye disease, he feels it's vital to know all the options and be able to set clear expectations for patients. Lastly, the doctors discuss some of the exciting new treatment options in the pipeline. Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.

After getting her first pair of glasses at age 12 and seeing the individual leaves on trees for the first time, Pam knew she'd be an optometrist. As an adult, she struggled with her own dry eyes, which led her to focus on helping others alleviate their symptoms. Today, Dr. Pam Theriot advocates for 4 simple steps for a daily hygiene routine: Hydrate, Harmonize, Heat, Heal. Listen in to hear how Dr. Theriot is sharing her knowledge with the masses through her clinic, her book and now the metaverse: https://theomniverse.city/dry-eye-metaverse/Learn more about Dr. Pam TheriotFind her book "Alleviate Dry Eye"  Key Moments 0:48 Dr. Allen introduces Dr. Pam Theriot 2:05 How Dr. Theriot found optometry 3:17 Moving around as a military spouse 5:38 Creating a dry eye clinic 8:43 The path to self-publishing 13:48 Preparing patients prior to initial consultation 14:40 post-appointment follow-up communication 16:43 Dr. Theriot's 4 simple steps for daily eye hygiene 18:11 Recommending nutritional supplements with Omega fatty acids 20:57 Dry eye technology and treatments 23:03 The future dry eye treatments 25:48 The first dry eye clinic in the Metaverse 33:07 Eye care should be part of your daily health care Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.

This is a free preview of a paid episode. To hear more, visit sub.thursdai.newsFirst of all, let me address this from the get go, I'm not a material scientist! I am pretty good at finding information in twitter's incredibly noisy info stream. (hey, this is how I bring you AI updates every ThursdAI) Since LK-99 is potentially groundbreaking and revolutionary, I've compiled a twitter list of everyone who I found credible, interested and a source of new information, and there's now over 1.5K followers to this list alone!Since this clearly is interesting to a lot of you, I reached out to a few prominent people on this list, and asked them to join a twitter space, to try and stitch together an update on the current state of LK-99, replication attempts, history and lore, as it stands a week after the original papers release. If you found this interesting, you're the type of person who wants to stay up to date, feel free to subscribe and keep this Substack alive!First of all, let's do some level setting. Superconductors are real, we've used them in MRI machines for example, but the currently available superconductors need extremely low temperature and high pressure to well.., and the promise of a room temperature and ambient pressure superconductor is the holy grail of energy use. For a breakdown on what superconductors are, and what they can mean for the world, I strongly recommend this thread from Andrew Cote (published presciently a full two weeks before the LK-99 paper) or watch this incredible breakdown: July 22nd, the LK-99 arXiv day! On July 22nd, two papers describing “worlds first room temperature superconductor” were uploaded to arXiv: 2307.12008 - Sukbae Lee, Ji-Hoon Kim, Young-Wan Kwon (submitted by Kwon)and after 2 hours and 20 minutes another paper was uploaded2307.12037 - Sukbae Lee, Jihoon Kim, Hyun-Tak Kim, Sungyeon Im, SooMin An, Keun Ho Auh (Submitted by Hyuntak Kim)You may notice that the first two authors on both papers are Sukbae Lee and Ji-Hoon Kim, and in fact LK stands for Lee and Kim and 99 in the LK-99 name stands for the year 1999 they have started research on this.You may also notice that YW Kwon who submitted the first paper, is not included on the second one, and in fact, is no longer part of the Quantum Energy Research Institute (Aka QCentre) where he was a CTO (he's no longer listed on the site) If this shakes out, and SC is replicated, there's definitely going to be a Netflix series on the events that led to YW Kwon to release the paper, after he was no longer affiliated with QCentre, with limited information so let's try to connect the dots (a LOT of this connecting happened on the ground by Seo Sanghyeon and his friends, and translated by me. Their original coverage has a LOT of details and is available in Korean hereLet's go back to the 90sOn the LinkedIn page of Ji-Hoon Kim (the page turned blank shortly before me writing this), JH Kim showed that he started working on this back in 1999, and they estimated they have a material that contained “very small amount of superconductivity” and together with Sukbae Lee, in 2018 they have established QCentre to complete the work of their Professor Emeritus of Chemistry at Korea University, the late Choi Dong-Sik (1943-2017) who apparently first proposed the LK-99 material (following the 1986 bonanza of the discovery of high temperature superconductors by IBM researchers).Fast forward to 2017, a wish expressed in a last will and testament starts everything again Professor Choi passed away, and in this will requested follow-up research on ISB theory and LK-99 and Quantum Energy Research Institute is now established by Lee and Kim (LK) and they continue their work on this material. In 2018, there's a potential breakthrough, that could have been an accident that led to the discovery of the process behind LK-99? Here's a snippet of Seo Sanghyeon explaining this:Kwon Young-Wan the ex-CTOKwon is a Research Professor at Korea University & KIST, is the third author on the first arXiv paper, and the submitter, was previously the CTO, but at the time of the paper to arXiv he was not affiliated with QCentre for “some months” according to an interview with Lee. He uploads a paper, names only 3 authors (Lee, Kim and Himself) and then surprisingly presents LK-99 research at the MML2023 international conference held in Seoul a few days later, we haven't yet found a video recording, however a few reports mention him asking for an interpreter, and talking about bringing samples without demonstration and proper equipment.Important to note, that Enter Hyun-Tak KimH.T Kim is probably the most cited and well-known professor in academia among the folks involved. See his google scholar profile, with a D-index of 43 and has 261 publications and 11,263 citations. He's a heavy hitter, and is the submitter and listed as the author of paper number 2 submitted to arXiv, 2 hours and 20 minutes after paper number 1 above. In the second paper, he's listed as the third author (and the submitter to arXiv) and his contribution is acknowledged like so: An author, Hyun-Tak Kim (H. T. Kim),'s knowledge on mechanisms of both superconductivity and the metal-insulator (gap-nogap) transition highly contributed to writing the mechanism part. The knowledge was acquired over 20 years by processes of performing national projects including project [Grant 2017-0-00830] funded by Institute for Information and Communications Technology Promotion (IITP) in MSIT of Korea government in ETRI. H. T. Kim left ETRI on Nov. of 2022.In the first paper H.T. is not acknowledged, and is only mentioned in in reference no. 52 to his paper from 2021. Ok enough about the people Alex! Does the rock levitate? In January, QCentre youtube channel uploaded an unlisted video that showed magnetic properties of LK-99 and another video, with partial levitation is widely shared on social media.The partial levitation shown is attributed to the Meissner Effect and is a supposed proof of room temperature super conductivity. However, these two videos are inconclusive and are not enough for us to take QCentre claims at face value. The scientific community, having been stung by a recent incident surrounding a supposed room temp superconductor, where the evidence was apparently falsified (Dais et. al.) are not so easily swayed. Adding to that, the mess around the multiple papers, showing different theories, the lack of peer review, or independent replication, the surprised publication, and a rushed follow up publication, all makes people wonder, what is going on here? This doesn't seem like a fabricated attempt. Summary of replication attempts so far (Sun, Jul 20) Given the importance of this discovery, and the “relative” triviality of replication, common enough materials, the process is not extremely complex (but kids, do not try this at home) so we can bet that “furnaces in solid-state materials labs around the world have been cooking yesterday and today to try to reproduce” [Science Magazine]We have reports from China that supplies of Led Apatite are running dry as many are trying to replicate quietly? Additional reports from India where Dr. VPS. Awana, the Chief scientist at CSIR-NPL and team are trying to replicate, with results expected as early as tomorrow (Monday, Jul 31) and has been emailing with LeeIn addition to this, we've had Andrew McCalip from Varda space who has been live-tweetin, twitch streamin his “Meissner effect or bust” campaign to reproduce LK-99, while the world watches (Andrew joined the space as well) and provides ideas, materials and an outpour of support for this gung-ho, almost cowboy effort. We've also had folks from MIT who claimed that professors who want to remain anonymous, and went to MML2023 are also in contact with the team and are trying to test the material.Replication failure is … not a failure? Discussing the replication attempts with experts on stage, we all concluded that there are likely 2 ways for the world to know wether LK-99 is a superconductor. * Replication succeeds and scientists analyze the replicated sample* QCentre team provides a sample, and some very smart independent folks put it under a microscope, a magnetism analysis and a bunch of other measurements and confirm that it's a superconductor at room temperature.While we wait for either of those, I encourage you to check out the resources, the space recording, and the list of folks I've collected to stay in the loop! Here's a list of relevant links: * Paper 1 DOI* Paper 2 Arxiv* Paper 3 Arxiv* New Scientist Interview* ChosunBiz Interview (Korean)* Yonhap Interview (Korean)* Twitter ListAnd the list of folks who participated in the space, give them a follow: * Alex Volkov (@altryne)* Seo Sanghyeon (@sanxiyn)* Ate-a-Pi (@8teAPi)* Andrew McCalip (@andrewmccalip)* Andrew Cote (@Andercot)* Ely Rabani (@radsci)* Robotbeat (@Robotbeat)* Marsh Ray (@marshray)* Ben (@BenShindel)* Ken Condon (@KenCondon1)* Jesus (@jesuslares_me)* Danielle Fong (@DanielleFong)For your convenience, attached is an AI transcription of the space with speakers and timestamps (may be off by a few minutes) : [00:02:40] Alex Volkov (@altryne): Hello. Hello, everyone. There's a lot of you here, and I wanna welcome a shoot for up on stage while we wait for a few more guests, and then we can get started. Thank you so much for taking the time joining us. as you're as interested as all of us in this very exciting, very confusing, very potentially groundbreaking news. So I wanna introduce 2 folks up on stage 2 folks up on stage already, and bringing up another one just now. And hey, Andrew. Hey.[00:03:18] Alex Volkov (@altryne): Hey, How are you guys?[00:03:23] Ben (@BenShindel):Doing well. How are you?[00:03:27] Alex Volkov (@altryne): A little bit you know, the palms are a little bit sweaty. This is a insane turnout. Twitter is indeed a public space on because that we have. And, hopefully, spaces or two spaces, whatever they call it now, will hold. And I only invite Sam here to speak as well. Hey, Tobias. How are you?[00:03:51] Ate-a-Pi (@8teAPi):I'm good. I'm good. So good to good to, you know, hear from you guys in person, Alex. Thanks for putting the space together.[00:04:00] Alex Volkov (@altryne): Thirdly. Andrew, we're gonna introduce Andrew, but many folks who are here already follow you and and follow your work. How how's your evening going, Andrew?[00:04:12] Andrew McCalip (@andrewmccalip):Lee, this has been a wild ride. Thanks for putting all this together. It's gonna be great to get all the information in one place for the first time. This is my first time experiencing the full volume of the Internet, and just been a a lot of fun to see all the positivity around the progress.[00:04:29] Alex Volkov (@altryne): That's great. So I'll do my best that, you know, Mother think this. I will maybe preface this that I am not a scientist. Many of the terms that we'll hear today in the space I've heard for the first time a couple of days ago. What I am is a Twitter for many, many years, and I have collected a a list of folks who I I personally wanted to follow to kinda see the updates as they roll out, and we've seen many, many things roll out very quick. with a lot of confusion and different replication attempts from different places. And I just compiled the list for myself. I started following.[00:05:08] Alex Volkov (@altryne): 8 to buy had incredible incredible content diving into the the timeline. I found I I wanna introduce thank you. Am I saying this right? I think you need to hit the the mute button in a mute. If this is your first time talking on RESTASIS. let me know if you're able to do that. And if not, we'll try to solve this. And out as I was collecting folks, And I I started seeing that Andrew started doing their application attempts and even doing Twitch.[00:05:46] Seo Sanghyeon (@sanxiyn):Can you hear me?[00:05:47] Alex Volkov (@altryne): Can you hear me? We can hear you. Hey, Sam Kim. How are you?[00:05:57] Seo Sanghyeon (@sanxiyn):It it it's the noon in South Korea, and I'm fine.[00:06:01] Alex Volkov (@altryne): the afternoon. Right?[00:06:03] Seo Sanghyeon (@sanxiyn):It's 1. Yes. Yes. It's the 1 PM.[00:06:06] Alex Volkov (@altryne): Awesome. And so I was just doing an introduction maybe as you were telling up, you maybe not heard some of it. However, folks in the audience who followed this kind of thread and how we came to be here I have a a thread that I'll post on top here that has all the folks from the Twitter list that I forgot. And San Kyung and his his team is basically the reason for the space. Me and Nathan kind of found Sunqun. Am I saying Sunqun correctly? Is that is that the right way to say this?[00:06:41] Seo Sanghyeon (@sanxiyn):My name is. Your your, yeah, your pronunciation is not actually not.[00:06:48] Alex Volkov (@altryne): Okay. I'll I'll turn my best to put months at the at the right names. And so we both me and 8 to 5, a a 34 in Saint Kyung, who's in Seoul currently, and definitely speaks the language we don't speak, and so there's a lot of insight and translation. And so, yeah, I guess we'll will get started, so feel free to present yourself, and then talk a little bit about your last few days and how you came around getting in this topic. and then how kinda what you found so far.[00:07:28] Seo Sanghyeon (@sanxiyn):I I didn't really expect to to speak.[00:07:30] Alex Volkov (@altryne): That's okay. That's okay.[00:07:32] Seo Sanghyeon (@sanxiyn):That's put me put me on the spot. Yeah.[00:07:34] Alex Volkov (@altryne): I don't wanna put you on the spot, but give us maybe a brief summary.[00:07:44] Ate-a-Pi (@8teAPi):Maybe maybe do you do you want me to help Sanyon?[00:07:47] Seo Sanghyeon (@sanxiyn):Yes, please. Okay. You you have read my right top, so maybe maybe you can explain what's going on.[00:07:57] Ate-a-Pi (@8teAPi):Okay. So I'm I'm just gonna I'm just gonna just to preface everything, I I'm writing a work of fiction. So all of you guys are just participating in an experiment. So but I'm trying to keep everything to kinda, like, factual and trying to interpret what what is kind of happening on the ground. Right? Shyam is much more factual, and he he has actually been doing a primary source work. So he's been actually digging up the actual Korean language science papers. He's been sitting down with friends They've kinda, you know, summarized and kind of tried to understand what's going on.[00:08:36] Ate-a-Pi (@8teAPi):And he's really the one that's, you know, put together this that that the you know, the the the mentor, you know, whose name, I think, in some transliterations comes out to TS's chair, some Donsick He the mentor was basically in superconductors in this idea of this kind of 1 dimensional super and he had this theory.[00:09:00] Seo Sanghyeon (@sanxiyn):That so the name is che. che. Oh, sure. Yeah. Yeah. Yeah. He was a a professor in the Korean University's Department of Chemistry.[00:09:13] Ate-a-Pi (@8teAPi):Yeah. And and so he he had this idea, this theory, and he had graduate students. and one of those graduate students was Lee, and Lee kind of took up the mantle of this this theory. And then they, you know, tied up with who was an experiment list.[00:09:37] Ate-a-Pi (@8teAPi):And then they kinda discovered this trace this coast of a trace of a material in 1990 And at that point, what happens is having discovered this trace, their path kind of diverge this, and Kim, the experimentalist, goes on to do a masters, not in superconductors. So he does his masters in something else, and then he does the battery materials kind of PhD, and he graduates in 2008.[00:10:12] Ate-a-Pi (@8teAPi):while Lee continues on the superconductor path, does experimental any when he publishes his PhD. It's both a theory and synthesis of superconductors. And then he graduates, and then he he goes to work as a science adjunct professor, which we which we just found out. Like, a computer science adjunct professor, and he's there for about, you know, 4, 5 5 years. He doesn't publish. And and I'm guessing at this point, he kinda gets, like, you know, cashier out of out of academia completely, and he sets up a consulting firm, basically, Q Center.[00:10:50] Ate-a-Pi (@8teAPi):And they start taking on consulting work. And and then, again, the timeline is a little bit unclear on whether or not they continue to work on on the on on the product on what they discovered. And what happens then is in 2017, Chey Dongksik passes.[00:11:18] Ate-a-Pi (@8teAPi):And as he passes, he he gets his former students together, and he asked them to finish off what they started to find this superconducting material that they saw a ghost of a trace of in 1999. And he passes, and they have no money. basically. Song Young has done, again, primary source research, and, you know, the the office space is basically, like, like, a two story building, you know, somewhere in the you know, in in Seoul. It's a very modern kind of office. They don't have much money.[00:11:57] Ate-a-Pi (@8teAPi):My guess my guess is that they need Kim. because KIM is the experimentalist, and I'm guessing also that none of the theory works at this point. The only thing that they have to go on is that they actually did find something in 1999. And Kim, I'm guessing, is also quite practical because he didn't do he didn't pursue the superconductors for the PhD. Right? Because he's quite practical, he's like, dude, you get me money. I'll join you. You don't have money. I'm not joining you for your wild goose, Jason. Right?[00:12:36] Ate-a-Pi (@8teAPi):So Lee goes out and he recruits Kwan. And Kwan is kind of like you know, he's he's a US PhD. He has a research university, you know, position. recruit them, and they get funding. And I think I think Sam Young, you were you were saying that Kwon is the one on the, you know, National Science Foundation of Korea's like you know, list, like, grant. Right? I I think that's what you said.[00:13:08] Seo Sanghyeon (@sanxiyn):So the paper mentions the public grant from South Korea. called the National Resource Foundation, which is like National Science Foundation in United States. And Korn is listed as a primary invest mitigate our PI, if then.[00:13:25] Ate-a-Pi (@8teAPi):Right?[00:13:26] Alex Volkov (@altryne): Mhmm.[00:13:27] Ate-a-Pi (@8teAPi):Yeah. Yeah. That's right. Okay. So he he's the PI. So they recruit him as the PI, and Jade Kim, who is, you know, Lee's partner, basically leaves his very comfortable position as a research director in a hearing aid test.[00:13:44] Seo Sanghyeon (@sanxiyn):Yeah.[00:13:44] Alex Volkov (@altryne): Yeah. Yes.[00:13:45] Seo Sanghyeon (@sanxiyn):Yes. Yeah. Hearing aid Yeah. I Or the eye test there? Yeah. Yeah. For the ISER tech and in manufacture, the battery is specialized for the hearing aid. code. It is a medical device. They have a different standard from other batteries. And company a small business in South Korea, but seems competitive worldwide.[00:14:13] Alex Volkov (@altryne): So he leaves his let me let me -- Yeah. Go ahead. Just real quick and to give folks a quick summary. The main paper that we saw the explosion from that was published on July 22nd, so a week and and almost a day we're, like, almost 8 days into this. The three people that you you just said, besides the first professor, Choi or chair or Troy and or several places write it separately. So the the three people, SoftBank, Jihoon Kim, which is the LK in LK 99, right, Lee and Kim. And the third person you just mentioned is Young Wan, Kwan. Yes.[00:14:52] Alex Volkov (@altryne): Those are the the 3 authors on the paper that kind of was published on our side out of the blue. 8 days ago. Please continue.[00:15:03] Ate-a-Pi (@8teAPi):Right. And then so at this at this point, they're in 2017, And, you know, Lee goes out and does the fundraising. He recruits Kwan, who's the research professor, Kwon is basically he's on the paper. He he's he's the principal investigator on the grant, but he's still a professor at university. So he's basically, I'm guessing, like, a day a day in the, you know, in the office at Q Center, very modest place. I think the grand size is pretty small, and they get this ESR machine.[00:15:41] Ate-a-Pi (@8teAPi):And again, from what I can tell, the ESR machine only came knows how to use it. Because none of the other people are actually synthetic, you know, synthesis people. They're all like theory guys, Kuan is a physicist. And Kim himself, JH Kim himself, he's looking for something which you have to know what you're looking for, right? Because that's what he says in his LinkedIn. He's like, I'm looking for some if you don't know what you're looking for, then forget about it. Right?[00:16:19] Ate-a-Pi (@8teAPi):But he he knows what he's looking for, and they refine, they refine, and they refine, and he keeps doing experiments. He keeps refining the experiment, and he goes through, like, a 1000 iterations. And somehow, starting in 2018, somehow, By the middle of 2018, they find it. So that that's a surprising thing for me because they've I I I suspect they they've been working on it you know, before or, you know, Jay and Lee had a breakthrough on their theory, so they knew how to narrow the workspace down. But somehow in at the end of the day, Kim is the one grinding.[00:16:58] Ate-a-Pi (@8teAPi):Through that 1000 experiments, finally, to get, you know, a sample that works.[00:17:03] Seo Sanghyeon (@sanxiyn):And then they start by -- No. No.[00:17:05] Alex Volkov (@altryne): No.[00:17:05] Ate-a-Pi (@8teAPi):No.[00:17:05] Alex Volkov (@altryne): No.[00:17:05] Seo Sanghyeon (@sanxiyn):No. No. No. No. No. No? So so besides the two papers, there is a paper published in April returning query. And In their own words, they describe what what prompted their breakthrough in 2018.[00:17:27] Seo Sanghyeon (@sanxiyn):and it said that so so they are putting the material in a quartz tube And because they called it to best courts to cancel and Brooke, And the material left after the breaking of the glass was had the property they wanted. So so it was an accidental discovery.[00:18:02] Ate-a-Pi (@8teAPi):So can can you repeat that? Like, they what what happened? They put it in the quartz tube, and the quartz tube broke accidentally?[00:18:10] Seo Sanghyeon (@sanxiyn):Yes.[00:18:10] Alex Volkov (@altryne): Yes. Yes.[00:18:11] Seo Sanghyeon (@sanxiyn):I see. And and And that what's the breakthrough in 2018? I see. It's what I'm saying.[00:18:19] Alex Volkov (@altryne): Yeah. I just wanna confirm what I hear. The breaking of the course you led to the incidental discovery. This is this is the the breakthrough as it's written in the first paper in Korea? Yes. Yes. Okay. So I'll just call ASAP, I'll just give it back for some logistics. Folks, if you look up on on top of the space, there's a few tweets we're pinning. And as we go along, we're gonna add some information on top of this. The 3rd the third we pin from dystopian breaker has a link to the original kind of Korean paper. So please go ahead, Datapai.[00:18:54] Seo Sanghyeon (@sanxiyn):So so quick -- Okay. point.[00:18:56] Alex Volkov (@altryne): Yeah.[00:18:56] Ely Rabani (@radsci):Go ahead. Go ahead. This this could be important because, you know, as as soon as you expose it to the atmosphere, your getting hydration. And hydration, you know, might be harmful, might be helpful. From this, like, little account, it seems like it it it either didn't do anything or was helpful. But, like, no what temperature it was at when it broke, and and things like that could could actually be really pertinent.[00:19:30] Ate-a-Pi (@8teAPi):Yeah. So, absolutely, like so it's not they he does do the 1000 experiments, but the 1000 experiments, whether that gets him there or not, at one point in the experiment, the quartz tube breaks, that gets them there. They get lucky. Right? So they get they get lucky. And then after that, things proceed pretty quick They isolate they isolate it, and then they they get the crystallization. They start working on the papers. They start on the patents, and they start also trying to figure out the chemical vapor deposition process. They seem to have made some way some headway on the chemical vapor deposition process.[00:20:06] Ate-a-Pi (@8teAPi):And then, you know, sometime around September 2021, something start happening. Quant takes a position, sabbatical at, I think, Seoul University at that point. I'm not sure whether that means he's putting more time in the office or not. And then that fast forwards to yeah. Go go ahead, Sunggham.[00:20:33] Seo Sanghyeon (@sanxiyn):No. No.[00:20:33] Alex Volkov (@altryne): No.[00:20:33] Ate-a-Pi (@8teAPi):You go ahead. Okay. So that fast forward about March 2023 when basically the international patent has been filed. And Kuan leaves the team at this time. I'm not sure when Kim comes on board. That's not very to me at what point Yum Tuck comes on board.[00:20:57] Ate-a-Pi (@8teAPi):So I'm guessing it's after the nature, the nature paper gets dinged in 2020, And and and, you know, the the other thing that strikes me also is that every single person on the team is very aware of every single hoax in superconductors to date. Right? They they they all know the space well, They've seen every single hoax before. They know they know what the hoaxes look like. They know what to look for. They know what diamagmatism is. So I I I don't think yeah.[00:21:29] Seo Sanghyeon (@sanxiyn):Go ahead. So the date is So the day before the yesterday, Andrew McCully posted on his Twitter the translation of the Korean paper at Doctor Lloyd. Is that correct? And can can you so so how did you translate and can Can you say something about it?[00:21:59] Alex Volkov (@altryne): Andrew, I think he's Frank to you. So I can just ring to you. You posted a translated paper also. Right?[00:22:08] Andrew McCalip (@andrewmccalip):Yes. Now that was just a machine translation from Google. That was just a very cursory translation.[00:22:19] Seo Sanghyeon (@sanxiyn):Okay.[00:22:19] Ate-a-Pi (@8teAPi):So in basically, quantity is team in March, and then you have the kind of papers being released, you know, haphazardly. The next the next point that of them is that they had started releasing the papers app as early, like, late last week.[00:22:42] Alex Volkov (@altryne): And and then and then we have -- And by the way, I think it's it's important to highlight by Kwan, the guy who's no longer affiliated with with QCenter. Like, this this sole endeavor a business venture that's funded for for this for this purpose. Kwan is no longer affiliated with that. We've seen Sankyo posted an interview in Korea from Friday where I think both of the and Kim say that Kwan, the guy who published the first paper, is no longer affiliated.[00:23:12] Alex Volkov (@altryne): there were some speculation as to maybe the limit of three people on the paper is the limit of the Nobel Prize or 2 or 3 authors. I don't have this confirmed, but this is speculation going around. And it's important to note like, both of them say that the paper was not ready when it was released, and it was released by Juan, the guy who left the first paper. 2 hours later, 2 than 20 minutes later, another paper gets released in the in the same archive with, I wouldn't say, 5 authors. not including Kwan. Right?[00:23:48] Ate-a-Pi (@8teAPi):So Lee -- Yeah. And -- The user the the user name is TumTuk team, the the college professor from, you know, Virginia is the username who who pushes the r archive paper at that Yeah.[00:24:04] Seo Sanghyeon (@sanxiyn):Chantakim is a big name with the 18 days of 45, and If you look at the paper, there is an error message in Korean saying that Bloomberg could not be found. It is a neutral error message when you did the some of the typesetting wrong.[00:24:27] Seo Sanghyeon (@sanxiyn):And You just don't probably see the room temperature, sugar conductor paper with the error deaths that had to bookmark cannot be found if you are following if you are in not in emergency.[00:24:52] Alex Volkov (@altryne): So so it does feel to us at least from the summary so far that the paper that Quang released has different information than than the second paper, and the second paper feels like it was released in the Harry and included more people that currently work at Q Center, including Hyundai Kim. And Sonja, owner, you this question. You mentioned his h h score or something score. Can can you explain the importance of that score for him talking?[00:25:20] Seo Sanghyeon (@sanxiyn):creates someone else to the explanation.[00:25:24] Ate-a-Pi (@8teAPi):Okay. So so the h score is, you know, because we have a web web savvy audience here. It's kind of like a page rank for, you know, researchers. It shows you how influential how influential the researcher was, and so a higher score means that more people have been citing your paper.[00:25:45] Ben (@BenShindel):Go ahead, Ben. Yeah. More precisely. So, like, an h index of, say, 40 means you have 40 papers that each have 40 citations or more. That's a little tricky to understand. So, like, if I get another paper that has only 30 citations, it won't affect my h index at all. I have to get a 41st paper that has 41 citations to to to make it rise.[00:26:07] Alex Volkov (@altryne): So I think it's it's safe to say HUNTAKIM, the guy who submitted the second paper, potentially haphazardly. Correct? Like, we're we're we're saying there's 2 hours after the first one. So likely prompted by these events is a well well sighted very well sighted scientist with a very high kind of confidence score. It's not like a random person of the street that decide that there's now a superconductor of room temperature and, you know, verified it.[00:26:41] Seo Sanghyeon (@sanxiyn):Okay. Sorry for being side tracked, but I just checked the the motion related to Korean paper or not to talk through it by Andrew. And on the page 5, we clearly said that the quartz tube was destroyed due to internal pressure during rapid cooling of reaction and etcetera. So I think, in fact, nobody really read ready carefully. It is it is just there about the quartz tube once destroyed.[00:27:19] Ate-a-Pi (@8teAPi):Yeah. So I think I think it's yeah. Definitely, like, probably the the rest of us are are are not very close readers. of of that paper.[00:27:29] Seo Sanghyeon (@sanxiyn):So so We can we can continue on after the upload to the archive.[00:27:42] Ate-a-Pi (@8teAPi):Indeed. So okay. So they they they it goes into our our archive, and then all of the events of the last week happen you know, I don't think any of us expected any of the events to happen. So we've all just been kind of, like, following along and seeing what happens next. I had no idea that there was a metallics conference in South Korea, and I I definitely had, like, no idea that you know, one of the authors would show up there, and it gets posted on Twitter. And so and then and then Seung Young points it out on the FM Korea Football message board.[00:28:20] Ate-a-Pi (@8teAPi):And so we translate, you know, what the audience reaction was in in in a bad translation to get -- So -- -- whatever message was across.[00:28:30] Alex Volkov (@altryne): -- mind let me interject here because this is around the that I found out about this. Alex, frozen coffee. Alex, I forgot his nickname. We invited him here. He posted a a very long Twitter thread that got the attention of the algorithm and then boosted of this room template ambin pressure, superconductor paper from Korea. I think he only started talking about the first paper, and then after the second paper also came out. And I think at this point, or somewhere around there. Andrew, you found out about this. What what did you first hear about, you know, Twitter drama around LK 90 Right?[00:29:08] Alex Volkov (@altryne): And, Andrew, feel free to at least produce you know, introduce yourself officially and BARDA and how you're interacting with this.[00:29:16] Andrew McCalip (@andrewmccalip):Yeah. So I was just cruising the Internet at night, and this came across. I think my my Twitter feed And so I I'm incredibly curious. This is something that has been a bit of a a hobby for me. And so I was always interested in superconductors, so it it caught my attention. I'm a mechanical engineer. So full disclosure. I am not a subject matter expert. I am simply an aerospace engineer that has a lot of curiosity and some assets at his disposal.[00:29:50] Andrew McCalip (@andrewmccalip):And so reading this paper, it it struck me just the simplicity of of the process. And so I realized that I probably had the ability to replicate with full fidelity, the process that was described in the paper. And so that within about 30 minutes, I I realized I should simply start down this road that Twitter was already picking up at the time.[00:30:21] Andrew McCalip (@andrewmccalip):There's some conversations going back and forth and the it was the classic scenario where on every superconductor discussion, there is the same conversation that happens over and over again. And this synthesis appeared so simple that it seemed that the most expedient thing was to simply test it physically. And so my my work is very receptive of of after hours projects. I'm I'm known as the the guy that has really aggressive hobbies, let's say.[00:30:57] Andrew McCalip (@andrewmccalip):And so I'm always in the back doing something interesting with materials or automation. So within 30 minutes of reading the paper, I had ticked off orders to various chemical suppliers. I've reached out to overseas vendors. to try to procure a couple of the the elements. And so it was just kind of an offhand comment that I made on Twitter and and then the ball really started rolling, and I realized that everyone wanted to see this this made.[00:31:32] Andrew McCalip (@andrewmccalip):And so it was just supposed to be a a a fun little project, but I was really overwhelmed by the the response. Everyone wanted to to see this done. I think there's this incredible curiosity, there's this incredible drive. People wanna see, like, incredible things happen for the the the human race. And so something if this magnitude pops up, everyone's motivated to drop everything and investigate. And I think that's where we're at.[00:32:08] Alex Volkov (@altryne): And I think you met the algorithm at the right place where folks were excited about the future and think this could bring a lot of changes around the future, and you started saying, hey. You know? Here's a here's a direct approach. Let's try to replicate this. And I I wanna just highlight the fact the the materials involved in creating this. And the process, some folks say and please talk about this. Some folks say that has been an attempt at a hoax, it wouldn't be as simple. They wouldn't have released a simple instruction manual kind of quote, unquote simple that many labs around the work they replicate given the materials and and the right equipment. Right?[00:32:48] Ely Rabani (@radsci):So -- Yeah.[00:32:48] Alex Volkov (@altryne): So -- -- straightforwardness of this potentially shows some stuff.[00:32:51] Ely Rabani (@radsci):So this this is a good time for for a PSA. I mean, I know that that Andrew is well aware of this, and and and many of peep of the people who've been following it. But in case anybody who's listening isn't. The these compounds in vapor form at any rate are are highly talked music, and you you have to know lab safety. If you're gonna start trying to experiment with them, you need things like, a glove box and, you know, all kinds of PPE, a fume hood, everything else. Taking risks with this kind of thing is just really not worth it.[00:33:31] Alex Volkov (@altryne): I I I can't stress that. Absolutely. Don't try this at home.[00:33:36] Andrew McCalip (@andrewmccalip):kids definitely. Yeah. Absolutely. There's a lot of chatter in the beginning in the first couple hours about this can be replicated in a garage And, you know, I thought it was interesting. I thought maybe we've got the opportunity to to do it safely. we've got all the right equipment. We've got, you know, the the 1,000,000 of dollars of equipment that support our spacecraft business. that allow us to do some of these things safely. And so I thought Twitter wants to live vicariously through somebody why not do this?[00:34:12] Andrew McCalip (@andrewmccalip):I ended up being in sort of an interesting middle ground because I'm not in academia. I'm also not trying to commercialize any part of this tech. really just doing it for fun because it's incredibly interesting. So I've got no skin in the game except for making this work in a transparent manner. and then getting the materials into the hands of the experts.[00:34:34] Andrew McCalip (@andrewmccalip):So I thought if we can leverage some of our equipment and some of our, you know, very smart people that we have, to speed this timeline up, I didn't see anybody in the United States being vocal about trying to do replication there are so many stories coming out of other parts of the world that all the labs, there must be thousands of furnaces burning right now trying to replicate this. But I wanted to get material into the hands of some local experts in California.[00:35:09] Andrew McCalip (@andrewmccalip):And so that's really our our goal is, you know, can we can we sort of be the face of of the Internet do this experiment in a safe manner and then help advance the science and be sort of a forcing function to to doing this replication.[00:35:27] Alex Volkov (@altryne): So, Andrew, just before just a a small pause before you continue, I want to ask the other, Andrew, here. The Andrew code, if if you're able to unmute and and and talk us if you're available about the potential reasons why all of Twitter jumped on this. Andrew Kot, you had a thread on room temperature superconductors. About 2 weeks before this, like, almost a permanent is kind of a threat. And could you give us some summary first of all, feel free to introduce yourself, but also some summary of what this means if this replicates, what this means for the world.[00:36:07] Alex Volkov (@altryne): Applications, you know, give us, like, some excitement of what happens if this is an actual ambient pressure in room temperature superconductor? Andrew? Does not look like Andrew is Oh, hey.[00:36:33] Andrew Cote (@Andercot):Sorry. My my audio cut out for a second. I I missed the prompt. Oh, here you are. Let you only -- Sure. Yeah. Thanks. Thanks very much.[00:36:44] Alex Volkov (@altryne): So so folks so so I I explained to folks your thread about MBN, you know, pressure room temperature superconductors that you've offered, what, 2 weeks before the paper came out. And then suddenly, this dropped. And I wanted you to highlight some of the potential applications of superconductors and give us some of the highlights of what happens in this replicating. This is an actual, you know, real thing.[00:37:08] Andrew Cote (@Andercot):Yeah. Sure. So it's kind of a funny thing. Yeah. I put that thread out there 7 weeks before this story broke. You know, just I have worked with this kind of stuff in in a few different areas now, so it's very, you know, superconducting radio frequency cavities are standard technology in accelerator physics to fill these to work in.[00:37:31] Andrew Cote (@Andercot):Like, my first job in physics was actually in a condensed matter lab using a a scanning tunneling microscope to look at, you know, electronic structures of potential high temperature superconductors So this has always been sort of like a holy grail of material science, like sort of a holy grail of applied physics. It's one of these properties it's one of these materials where the bulk properties come from its quantum mechanical behavior. And and, you know, when quantum mechanics and its effects escape the realm of the very tiny, it can really manifest as as magical phenomenon at our scale in the world of the kind of the bulk matter or the big stuff.[00:38:10] Andrew Cote (@Andercot):So, you know, superconductors are used currently today, You know, it's it's they've reached engineering applicability through decades of continuous refinements and improvements. And and some of the biggest things to think about in what lets these things get used in industrial applications is their ability to superconducts at higher and higher temperatures And, also most also importantly, is to operate at higher and higher background magnetic field strengths. And so the way to think about this is that a superconductor, it's allowing current to move through it with zero resistance, but it also perfectly spells magnetic fields.[00:38:48] Andrew Cote (@Andercot):And there's an operating point of these materials where it's basically the current density and the temperature and the magnetic field kind of put the bounds or the performance envelope on the material. So some conductors can carry tons of current, but they can't exist in a very high field. And so, you know, those are hard to make as useful. You can use them for carrying, like, electricity, which is awesome, but often what you really wanna do is generate very strong magnetic fields. So I think maybe the most familiar to the most people here would be, like an MRI machine. Right?[00:39:27] Andrew Cote (@Andercot):Magnetic resonance imaging. So the idea there is you're generating very high strength field, and magnetic fields are measured in Tesla, for example. So just for just for context, you know, 3 Tesla is a is a pretty strong field, and that's what is about the strength using an MRI. So, you know, MRIs use these cryogenically cooled magnets, or or they're not I don't think cryogenically cooled. They're actually often just copper, but they do have cooling. But they generate this high strength field, and then, you know, it kind of sets all these little protons in your body spinning and dancing in a little, you know, kind of radiating energy.[00:40:03] Andrew Cote (@Andercot):And then you have a pickup coil, which is like an antenna, and the antenna is trying to pick up that energy and kinda reconstruct what's going on in your body. And this is how we can get, like, a really high detailed, high fidelity, three-dimensional image of what's going on inside someone without any invasive surgery. So it's, like, you know, MRIs are a real kind of amazing breakthrough in medical imaging. Superconductors if they could work without cryogenics would really simplify and make cheaper and more available, high resolution, high fidelity, three d images of people's bodies.[00:40:35] Andrew Cote (@Andercot):not just for making the magnetic fields, but also for picking up the signal emitted by the protons that get put into motion by the field in the first place. So it's kind of, like, one sort of off the shelf example. I think another one that's kind of under the radar, we don't think about it's not just in carrying electricity without resistance, which is useful for long range, like energy transmission, that kind of stuff. But if you look at the national grid, I mean, only 5, 7 percent of energy total, which is still significant, but it's, you know, single digit percentage ends up, you know, burning as weight You're suddenly muffled.[00:41:11] Alex Volkov (@altryne): I don't think yeah. You're suddenly a voice like your -- Oh, better.[00:41:18] Andrew Cote (@Andercot):Now it's better. Okay. Sorry about that. Yeah. So just gonna say so, you know, National Grid Scale Energy Production. Right? So trans transmitting the energy to its endpoint consumption, there's a bit of waste heat along the way. But what's what's also important to think about is how that energy is produced. It's produced also using high strength magnetic fields. And I was looking into this. There's a a experiment where these guys used sort of more modern high temperature superconducting tape to, you know, retrofit a large DC generator then it had, like, a 36 percent power improvement, right, which is pretty substantial. That's that's a that's a serious win.[00:41:58] Andrew Cote (@Andercot):Yeah. So there's there's, you know, sort of thousands of places this stuff could be used that would really just, like you know, it would either greatly improve the performance efficiency, reduce the cost, increase the accessibility of what we think of as, like, high technology like MRIs or particle accelerators. But it would also just decrease the cost of basic things like electricity generation and distribution And that's just the beginning. Right? So, you know, this kind of stuff there's a really good analogy here actually with the transistor, you know, for for years, scientists, then electrical engineers and physicists, they had this idea of a transistor. Right?[00:42:35] Andrew Cote (@Andercot):If only we could have some kind of simple, reliable, current model supplier. We could design all these wonderful things. We could design all these different kinds of logic functions and so forth. And so there was this search for the transistor people were searching for something that could do that, and they had anticipated all the places it could be used ahead of time. And it wasn't until at Bell labs, you know, a very kind of funny crossover here. One of the guys that's on the patent for the transistor is John Bardine. and John Bardeen's actually the only guy to win 2 Nobel Prizes. 1 was for the transistor. The other was for the theory of superconductivity, right, which is Barting Cooper Schiffer Theory, BCS.[00:43:14] Andrew Cote (@Andercot):So, again, it's one of it's one of those things where, you know, physicists, scientists, engineers kinda thought about this for a long time, realize this be amazing. And there's been this, you know, really complicated random walk through the configuration space of possible materials, right, which is so high dimensional. There's so many things you can construct. So I think it's I'm very optimistic about the field in general. I think one thing to think about with this particular result there's so much artisanal craft and and mastery that goes into producing these materials in a reliable, consistent way You know, science people don't often recognize. It's a lot of art involved too. Right?[00:43:52] Andrew Cote (@Andercot):Like like, things that are reduced to expert practice us and know how. And so I'd I'd just be cautious on, you know, jumping to conclusions either on this particular result, if it's if it's valid right now. But, also, if some labs can't fail to reproduce it, it doesn't actually rule it out entirely. I I think there's scientists that have traveled to Korea to work with the original authors. I look closely at that. You know, I'd also you know, I my internal odds are kind of like a 1 in 6 chance, this pans out, and it and it could be big.[00:44:21] Andrew Cote (@Andercot):But that doesn't mean that it's the end of the search or the end of the race, and I'm and I'm also optimistic that Getting people to understand what the massive long term and large scale social benefits of this kind of discovery could be could help direct a lot more basic science research towards this field. You know, I think we spend a lot of things on, like, how to make smartphone cameras better and not a lot of things on and not as much as we could spend on things like high temperature superconductors. And this is a final example.[00:44:48] Andrew Cote (@Andercot):I mean, so right now, you know, I work as a accelerator engineer, accelerator is a type of magnetic confinement fusion reactor The reason the company I work for can't exist, and and the reason there is this current burn and boom in nuclear fusion, is because we've engineered these high temperature superconductors to work in higher and higher magnetic fields, at at higher and higher temperatures. And and the big economic breakthrough there came when we can have these superconductors that can work at liquid nitrogen temperatures, right, which is 77 kelvin. And it's a lot cheaper to make liquid nitrogen and run that kind of cryogenics than it like liquid helium at, like, 4 Kelvin.[00:45:24] Andrew Cote (@Andercot):So, you know, we're already reaping some of the benefits of this sort of tech stack maturing over time. And I think really just getting started in terms of, like, the hunt for promising materials. I mean, I'm hoping this results in positive publicity and more effort, more energy, put into the field. I think if this doesn't pan out as the thing, you know, don't give up hope. Right? I mean, this is a long term game. Science sees by starts and stops. There's no fundamental physics here that's impossible. Right? There's no physical principle that says this can't work. Right? This isn't like a a momentumless or massless propulsion drive like the EM drive.[00:46:04] Andrew Cote (@Andercot):isn't, like, superluminal neutrinos. Right? Those things kind of break laws of physics. This is very much in the realm of, yeah, physically possible. seems seems very you know, in my mind, seems likely there could be something out there given the complexity of state space of electronic structures and given how you know, how large that space of exploration can be. And, yeah, so I think I'm just kind of you know, this is a great time to be interested in material science to appreciate basic science research and educating ourselves on on how good the future can be. You know, I think there's a lot of narratives right now in society and cultural in general. that kinda say, like, you know, you know, we we can't solve our way out of our biggest problems today. Right?[00:46:43] Andrew Cote (@Andercot):And and I'm very much on the other side of that debate. I think we can. I think it's through efforts like this. I think it's through people like Andrew at Varda that are willing to do stuff in their backyard or their garage or their fact or their their work workplace on their extra time. You know? I mean, this is the kind of this is the the let's build mentality. Right? And so I think we can build our way out of the world's greatest problems, and I its fundamental scientific advances like this discovery could be that that kind of paved the way out of there too. So, yeah, overall, very optimistic.[00:47:11] Andrew McCalip (@andrewmccalip):Andrew? That that's incredibly well said. That is an incredibly well balanced viewpoint. So how would you advise people to absorb the the next week of the new cycle? I mean, we're very much on a you know, we're we're back dead. We're back type of hype cycle. So how do you advise people to think about the results that they're seeing knowing that this is a a very difficult thing to replicate when it just because it a negative result is shown in a lab that doesn't mean it's not physically possible.[00:47:49] Andrew McCalip (@andrewmccalip):It's very difficult to prove the negative here. So tell us how we should absorb the new cycle coming up in the next few days.[00:47:59] Ate-a-Pi (@8teAPi):So I I I I I I might I might say something about that. I think I think this is basically tacit knowledge transfer, and you Kim Kim seems to have been this kind of, like, artisanal, like, you know, experiment list. So you need people to actually sit there in the lab with this guy, and he needs to demonstrate to them. And they need to pick up and and there might be things that he does, which he didn't write down. That that's the like, my my take on it given that He is the experiment list. He's the synthesis on on the team.[00:48:38] Ate-a-Pi (@8teAPi):Given that the team seems to have been only, like, 5 or 6 people, is that this guy is the maybe the only person in the world as of, like, you know, 18 months ago. I'm guessing that, you know, he managed to transfer some of that to the JungTux team. So I'm guessing that at at least one more one more team on on earth has this now. And I'm guessing that this knowledge transfer is now happening to a couple more people. So so you need to see this progress maybe 2 or 3 cycles for, like, a bunch of other people to have learned the skill, and then that's when that's when things get interesting.[00:49:14] Seo Sanghyeon (@sanxiyn):I mean, you don't really need to replicate to to verify this. There, the the team can just the team has the working samples. they can adjust the samples to the laps around the world.Hey, the rest of the episode is for paid subscribers to thursdai. I encourage you to subscribe or upgrade your subscription to access it, there's almost 2 more hours of in depth conversation, stitching of facts, experts on material science, physics, electrical engineering and MIT folks chiming in. It's really a great space, around 25K folks have listened to it on twitter so far.

Does seeing more clearly help you be a better leader? In this episode, Dr. Alison Tendler discusses her upbringing in South Dakota, experience in medical school, and what it is like to lead her team of 14 people. I called her green eyes blue. You may remember Dr. Tendler from the Restasis eye drop commercials that ran from 2008-2015 or so, with her striking green eyes, which I called blue during our face-to-face discussion. She let me off easy. Alison's story is an inspiration to young ladies who are considering a career as a Medical Doctor as well as medical professionals or anyone considering leaving the comfort of a large organization to start their own business. Learn more about your ad choices. Visit megaphone.fm/adchoices

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Kayla: Hi, I am working with an integrative practitioner right now. I have had a sharp pain in my lower left stomach, which she said it was a swollen lymph node. My candida antibodies came back extremely high, so I am currently taking antifungal herbs, as well as a probiotic and it my pain and symptoms seem to be getting worse. Do you think there are other underlying problems contributing to this pain? Or why do you think there is such a sharp pain in the lower left abdomen? Thank you so much!   Jenny: Hi Dr. Cabral - I am a long-time, dedicated podcast listener and am so appreciative of the information and insights you share. I am excited to now be a Ayubowan Member and look forward to receiving on going lab tests and coaching calls along with it. I follow the foundational protocol level 2 daily and also take your immune support products. My question has to do with the new longevity line of products that I am also excited to try. Because some of them include some of the supplements I'm already taking daily, how can I determine whether I should continue with my current supplements in addition to the longevity products? I have been reluctant to order the ones I'm most interested in trying because I am unsure. Much thanks to you and your amazing team!   Hans: how to rid the body of a fatty liver   Mally: Hi Dr. Cabral! Thank you so much for all you do, your podcasts and Equilife products have been SUCH a blessing for me and my family! I have ran a stool & organic acids test test through my local functional doctor, and have completed a 6 month bacteria overgrowth protocol through him. I recently tested for incredibly high levels of Ochratoxin A and started on your mold protocol. (His protocol called from some intense binders, so I did not feel comfortable taking those while my body is already herxing.) I appreciate how your mold protocol has less side effects. My question is, is your protocol able to address mold that has colonized in the sinuses and/or organs? My chronic sinusitis started when I was a kid and I am wondering what the proper expectation should be are far as recovery time. I have seen decent amounts of biofilm in my stool for about 6 months now. Also, is there any bloodwork I should be monitoring while I am detoxing so heavily?   Crystal: Hi Dr. Cabral! Because of my PCOS, I now have chronic dry eye syndrome. I have listened to all of your podcasts on dry eye that I could find and nothing seems to help. The only thing that has seemed to help the constant burning are Restasis eye drops that my eye doctor prescribed me. The dry eye suddenly started in Feb. 2020 out of nowhere and ever since, my eyes are really red and a large, visible, red vein has formed in my right eye. My eye doctor told me it will never go away, but I just don't want to believe that. My eyes have always been my best feature and I hate having red eyes all of the time and this giant red vein. What can I do to stop my dry eye and can I ever get rid of the red vein? Sorry my question is so long, but I so appreciate you taking your time out to answer my question and I value your work and advice so much. Thank you Dr. Cabral, you are my biggest inspiration!   Michael: Hi Dr Cabral what would cause someone to burp omega 3 capsules? I've tried many functional medicine brands but I keep burping them. I have low stomach acid, tested positive for h pylori and I probably have sibo as well. Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes & Resources:  http://StephenCabral.com/2270 - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -  Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Stress, Sleep & Hormones Test (Run your adrenal & hormone levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels)

In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eyecare, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology. Intro :10 Brief recap of episode 2 with Nicole Fram :55 News and Notes 1:31 Generic of Allergan's Restasis by Mylan Pharmaceuticals and discussion of generics in the ophthalmic space 2:05 Aramis Biosciences in phase 2 neuromodulator dry eye program and discussion of dry eye 5:12 Jim discusses Aetna's prior authorization for cataract surgery 6:54 Bilateral same day cataract surgery discussion 8:48 Eric Rosenberg, DO, introduction 10:48 What is digital? What is the meaning of digital? 11:38 Goals of the Digital Ophthalmic Society 17:33 Barriers to adoption of digital 22:34 What will DOS be discussing at Eyecelerator@ASCRS? 23:56 What Rosenberg hopes the DOS will achieve in the future 27:38 Thank you, Eric 29:42 Roger Ohanesian to receive Chang/Crandall Humanitarian Award at ASCRS 30:01 Sneak peek at the next episode 32:18 For more information: John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Eric Rosenberg, DO, is a cornea, cataract, and refractive surgeon at SightMD. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Rosenberg via email at ericr29@gmail.com. To learn more about the DOS, visit: https://www.digitalophthalmicsociety.com/. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Rosenberg at the time of publication.

Her recommended dry eye regimen includes making intentional changes to their daily activities – computer use, makeup products, eyelid hygiene and warm compress massages – these lifestyle changes are all a part of daily modifications that need to be done to make a difference. Prescription medications that reduce inflammation in the eye like RESTASIS® are a go-to option for any patient with SPK, reduced tear break up time, or symptomatic patients who are already utilizing high quality artificial tears.  The post Optometry Podcast: Dr. Neena James on Dry Eye and Working with Industry appeared first on Defocus Media.

As president and CEO of LENTECHS, a clinical-stage ophthalmic device company on the verge of commercializing a new contact lens, Robin Sears applies the core competencies he learned while moving through the ranks at Johnson & Johnson and Allergan.As told to podcast host Paul Karpecki, OD, when Robin heard about the presbyopia lens developed by Melissa Bailey, OD, PhD, and Joe Barr, OD, he saw a tremendous opportunity to reshape the market. He started fundraising and turned a novel invention into a business.Because of the demand for a presbyopia lens, that business may soon take off. LENTECHS research showed 74% of presbyopes who wear glasses want a contact lens solution. Why aren't they using one now? Visual compromise. Current lenses don't resolve near, mid, and far vision well enough for this growing population.The LENTECHS lens, called APIOC™, is based on a new type of contact lens-wearing experience. The lens is suspended behind the upper eyelid, which allows the eye to move freely behind the stable contact lens. It's like wearing progressives, but without the glasses. After successful clinical trials, the company is currently staging for commercial launch in late 2022.Listen to this podcast to discover:The LENTECHS MOA: How APIOC works with the eye's anatomy rather than on the eye's anatomy.How Robin helped build Allergan's then-new dry eye product, Restasis, into a billion-dollar drop. While there, he also led multiple teams to achieve billions in sales.The common traits needed to lead startup, continuing success, and turnaround opportunities.The full story on LENTECHS's rise from concept to company.What Robin learned from his earliest mentors: his father, a dairy farmer; and an MBA professor who literally wrote the book on taking biotechnology research from the bench to industry.

This podcast was recorded on February 23rd, 2021In Episode 1 of the Xtalks Life Science Podcast, Sarah discusses a new condition called “Mask-Associated Dry Eye” and Ayesha talks about Droplet Micron, an innovative insulin needle. Tune into this episode to hear a clip from Sarah's interview with Dr. Richard Hom, optometric director at Anthem Blue Cross and Blue Shield, who talks about the impact of prolonged screen time on eye health. And hear from Anu Rajora, director of medical marketing at HTL-STREFA, the company behind the innovative Droplet Micron insulin needle, who explains why technology needs to make it easier for patients to adhere to medication schedules.Read the full articles here:Why Mask-Associated Dry Eye Won't Necessarily Boost Restasis SalesPatient Centricity in Insulin Delivery: Improving the Injection Experience with Droplet MicronFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks, @XtalksMedDeviceInstagram: @XtalksFacebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn:https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

Kelly Giuffrida, Director of Marketing, for Restasis, at Allergan joins the conversation on innovation on episode 4. Kelly is an award winning healthcare marketer and leading innovator that sparks, shapes, and delivers meaningful results. Her futuristic outlook is fueled by continuous exploration of the latest innovations in Brand promotion. Kelly is known for initiating and leading insight based solutions that disrupt the status quo.

AB 243 Live! Envision the Experience with Nigel Travis and Alison Tendler   This episode of All Business with Jeffrey Hayzlett begins with Nigel Travis, Principal at Challenge Consulting, but who is better known for his time in leadership Dunkin’ Brands, Papa John’s, Burger King and Blockbuster. Jeffrey and Nigel talked about the importance of matching the cadence of the businesses you serve. For example, at Dunkin’, his executives were in the office before sunrise because that’s when their franchisees were at work. Nigel says businesses of all types have to imagine the future and those who have will survive the pandemic. He also talked about buying a professional football club in East London and how it’s adjusting without games for the time being. In the second half of the show, Dr. Alison Tendler joins Jeffrey. You may recognize Dr. Tendler from her years as the spokeswoman for the prescription eye treatment, Restasis. She now owns ART Vision and ARTisan Skin and Laser Center in Sioux Falls, SD. Jeffrey and Dr. Tendler talk about how her clinic handled the pandemic for employees and patients and how she was able to tie two distinct businesses together for the betterment of her patients. It’s all about providing a great overall experience.  C-Suite Supplies: https://c-suitesupplies.com/ C-Suite Loans: https://www.c-suiteloans.com/ Become a member of the C-Suite Network: https://go.c-suiteforums.com/executive-membership1585761368840   Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Dr. Suh interviews Dr. Ken Beckman about all aspects of dry eye disease. They first delve into the common signs and symptoms. Dr. Beckman then discusses the special tests that can be performed at your eye doctor’s office to confirm which type of dry eye disease you may have. Lastly, he does a comprehensive review of the wide-ranging treatments that are available today. Below are links to some more information about topics that are discussed on this episode.Tear osmolarity measures the salt concentration of human tears to aid in the diagnosis of dry eye disease.InflammaDry detects high levels of MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with chronic dry eyes.Lipiscan is a high-definition oil gland imager that allows eye care professionals to assess meibomian gland structureThis is one of the brands of moist heat eye compresses that Dr. Beckman recommends in his office to help patients with evaporative dry eyes – the most common cause of dry eye disease. Lipiflow is a procedure performed in the office that heats and massages the eyelids to improve outflow of the natural oil from the glands that are so vital for a stable tear film layer.This is a nice summary article about the three prescription dry eye medications – cyclosporine-A (Cequa and Restasis) and lifitegrast (Xiidra).Punctal plugs, a quick, in-office procedure covered by insurance, are a nice adjunct to combat dry eyes. Autologous serum drops are eye drops made from a patient’s own blood plasma and serum. Scleral contact lenses can be worn to treat severe dry eyes. This is an old article but still relevant.This is a nice summary article on dry eyes from the American Academy of Ophthalmology Dr. Beckman was one of the lead authors in this landmark, peer-reviewed journal article that changed paradigms about dry eyes.You can find out more about Dr. Beckman and Suh's practice at their website and on Facebook.This is intended for informational and educational purposes only, and nothing in this podcast/blog is to be considered as recommending or rendering medical advice or treatment to a specific patient. Please consult your eye care specialist for proper diagnosis and treatment of any eye conditions that you may have.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I’m looking forward to sharing with you some of our community’s questions that have come in over the past few weeks… Let’s get started!    Amanda: Hi Dr. Cabral! I love your podcast and appreciate all you do to share your knowledge and the gift of wellness. I have had chronic dry eyes for the last 12 years. Before I realized what was going on I’d wake and have extreme pain and watering in my eyes. Turns out I was having corneal erosions (corneal tears). As per my eye doctor, I quit wearing contact lenses and began using OTC tears as well as an ointment in my eyes at bedtime. I have done this for years. Corneal specialist said my cells were like a bumpy road rather than smooth and would get caught on the eyelids and tear. I have also had the inside of my (upper) eyelids abraded with silver nitrate 3-4 times. I have also been using Restasis for the last few months. Eyes are still dry, I still use ointment at night but I would love to get to the root of the problem and not have this constant worry that I’ll wake up with a painful tear. Thank you in advance!!! Jan: I notice my DNS shake has 250 mcg of methyl B12 and 400 Mcg of methyl folate. Other supplements I've taken have a higher ratio of b12 to folate...like 1000 Mcg b12 to 400 Mcg folate. Can you please explain your reasoning behind the lower b12/folate ratio in the DNS shake? (PS - I would love to hear a podcast just on the DNS shake itself, and how and why Dr. Cabral used specific ingredients and specific amounts when formulating it. It helps me to "visualize" what the shake is doing for my body - seriously! ) Andrea: Hi Dr Cabral. I went off the pill 5 years ago and got regular periods straight away, however, I have been struggling with missing periods the last 2 years getting it around once every 4 months. I have been working with my Naturopath, running tests and have been working to bring my thyroid number down from a 6 to currently a 3 amongst other lifestyle changes. I did get my period back in August on day 3 of my 7 day Cabral detox. Today (Dec) I started another 7 day detox and it is back on day 1! Could the timing be slightly coincidental or are the herbs in the detox tablets helping bring this on? Any insights into how I might achieve these same results when not completing a detox? Many Thanks. Audrey: Hi Dr. Cabral. I recently listed to a podcast on longevity featuring Dr. David Sinclair, Harvard professor and author of Lifespan. He spoke on Metformin, Resveratrol, and NAD booster how these are essential for longevity. I know you have referenced Resveratrol several times in your podcasts, but I searched and could not locate any specific podcasts. What is your take on each of these and is a Resveratrol supplement something that is safe to take and if so how many mg? Thanks so much for all you do! Melody: Hi Dr. Cabral! I love your podcast and everything you teach - you've been a lifesaver for me and my family. However, my PCP is a skeptic with supplements and puts doubts in my mind all the time. So I wanted to ask you about the Equilibrium Nutrition supplements - when you say they are third party tested, where can we find that information on the website or product description? I see the GMP certification - but from what I've read, all supplements need to be GMP certified in order to be FDA approved, is that correct? So by "third party testing" do you mean you use NSF as your third party tester? I'll feel better being able to explain this to my doc and friends if I know more about this. Thank you for being one of the best humans on the planet - I'm so grateful for you! Melody Thank you for tuning into this weekend’s Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes & Resources:  http://StephenCabral.com/1458 - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -   Dr. Cabral’s Most Popular Supplements: > “The Dr. Cabral Daily Protocol” (This is what Dr. Cabral does every day!) - - - > Dr. Cabral Detox  (The fastest way to get well, lose weight, and feel great!) - - - > Daily Nutritional Support Shake  (#1 “All-in-One recommendation in my practice) - - - > Daily Fruit & Vegetables Blend  (22 organic fruit & vegetables “greens powder”) - - - > CBD Oil  (Full-spectrum, 3rd part-tested & organically grown) - - - > Candida/Bacterial Overgrowth, Leaky Gut, Parasite & Speciality Supplement Packages - - - > See All Supplements: https://equilibriumnutrition.com/collections/supplements  - - -   Dr. Cabral’s Most Popular At-Home Lab Tests: > Hair Tissue Mineral Analysis (Test for mineral imbalances & heavy metal toxicity) - - - > Organic Acids Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Thyroid + Adrenal + Hormone Test  (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Adrenal + Hormone Test (Run your adrenal & hormone levels) - - - > Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Omega-3 Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - > Stool Test (Use this test to uncover any bacterial, h. Pylori, or parasite overgrowth) - - - > Genetic Test (Use the #1 lab test to unlocking your DNA and what it means in terms of wellness, weight loss & anti-aging) - - - > Dr. Cabral’s “Big 5” Lab Tests (This package includes the 5 labs Dr. Cabral recommends all people run in his private practice) - - - > View all Functional Medicine lab tests (View all Functional Medicine lab tests you can do right at home for you and your family)

Whitney Hauser : Hi. I’m Dr. Whitney Hauser. And welcome to Dry Eye Coach podcast. Today we’re going to be talking about tips for doctors just starting out in dry eye. So, if you’re looking for some new pearls about how to add dry eye in your practice, this may be the podcast for you. Today I’m joined by assistant professor at the University of Colorado Department of Ophthalmology, Dr. Rich Mangan. Welcome, Rich. Rich Mangan : Oh, thanks, Whitney. It’s great to be here. I appreciate it. Whitney : You bet. You bet. We’re kind of excited to get to know, you know, what you think are some of the greatest things that new practitioners, or practitioners that are just trying to bring dry eye into their practice might want to add in as they develop. So, I’m going to jump in with some questions for you… Rich : Okay. Whitney : … right off the bat. And, what are the benefits to doctors and their patients for getting started, or treating dry eye disease? You know, there’s benefits on both sides, so give us a little bit… Rich : Right. Whitney: … of your thoughts there. Rich : Right. You know, certainly, the benefit for me as a doctor in getting started was just to have a greater appreciation for the fact that ocular surface disease is in fact a real disease and not just a symptom. To be honest with you, years ago I used to hate dry eye. You know, I would go and see LASIK evals and cat evals and I was really enjoying that. And then I’d pull out a chart and it’d say dry eye and, you know, I’d just shrug in agony thinking about it. But then I went to a speaker training many years ago, in fact, this was around 2002 when Restasis came out, and it really, the panel did an excellent job of just really impressing upon the attendees that, you know, the quality of life scores of dry eye can really mimic, you know, even severe things like angina or disabling hip fracture. So, when I took that to heart, and I decided that it was time to come back to my practice and truly treat it like a disease. And so, I spent some time educating my key technicians, my team leader, and we actually carved out dedicated time just to really focus and concentrate on these patients. And what it did was, after they got to hear, you know, my walking the walk and talking the talk, you know, my dry eye practice really became more efficient because they knew what I was going to say before I was going to say it. And, but they truly developed appreciation for the fact that this is a disease. Whitney : Yeah. You raise a good point, you know, about the kind of parallels that are between more serious, as they would be noted, diseases and dry eye disease. I think that’s where a lot of the disconnect is. It’s not so much that the doctors don’t believe it exists. I think that most eyecare providers do. But it’s the gravity of it. So, the patient sitting across from them I think is oftentimes what’s missing. Rich : Yeah. Whitney : So, I think you probably latched onto that well in advance of a lot of our colleagues, including myself. So… Rich : Well, I’ve been around longer than you, Whitney. I’ve had a little bit of a head start in that respect. (laughs) Whitney : Unfortunately, not by as much as one would think. (laughs) You feel like this has a positive impact on new referrals as well? Bringing new patients into your practice? Rich : You know, it really does. Keep in mind, when I first started my dry eye practice I was in a co-management, a referral center, and one of the concerns we had when I brought this idea up was, how were our referring doctors going to look at this? Would they look at it like I was competing with them? And, in fact, the response was the complete opposite. They loved the fact that they had a resource in the area that really took this seriously. Patients could

This episode answers questions related to dry eyes, glaucoma, improving nearsightedness, UV lights, and blurry vision. Question 1 0:39 - 8:53 I have some questions for you regarding my mom's eye issues.  She has had a cornea transplant in her left eye and is having issues with it. She is on two medications:  Simbrinza 1% and Systane (both eye drops are taken twice per day).  Her right eye is getting very dry. I bought her the MSM drops you offer on your website.  She is using them several times per day in her right eye but says they don't seem to be relieving the dryness. I tried to speak to her doctor about using them in both eyes but did not get a nice response. I now have my mom taking the oral MSM along with the eye drops but she keeps having issues. Question 2 8:54 - 12:59 What would you suggest if I'm already on medication for the beginnings of glaucoma? Should I use with or taper over to MSM? Please advise because I fear this medicine I'm using may be harmful. Thank you. Question 3 13:00 - 18:17 Many health gurus are adamant that sunglasses should never be worn especially ones with polarized lenses. I do sun exposure without sunglasses early and late in the day but find I am more comfortable with sunglasses in the middle of the day and when I drive. Is there a particular problem with polarized lenses? Question 4 18:18 - 25:51 Hey Dr. Berne! I'll get right to the point: my vision is terrible (6.5 in the left eye and 7.5 in the right eye) and I'm only 23.  I want to improve my vision, maybe even get it to 20/20 if that's possible. I want to downgrade the prescription of my glasses a bit, as you've advised, to get my eyes working more, but I'm currently dealing with posterior blepharitis in my left eye, so my vision's blurry in that eye. I know I can reduce the prescription for my right eye and be okay, but I am not sure what to do for the left eye since the vision's blurry regardless. I've been doing your dry eye exercises at least 1-2 times per day. Any tips on what I can do? Question 5 25:51 - 30:21 I had cataract surgery on both eyes in June. Apparently, both of the implanted lenses were cloudy on the back. I have to wait until November to have a laser treatment to clear that up. However, I have what appears to be “blinders” on the outside edge of my vision. I was told there is nothing that can be done about it and that is from the incision. I am told it should go away in time but no one knows how long. Is there anything I can do to help this heal/go away? Question 6 30:21 - 36:27 Have you heard of Microsporidia Fungus growth causing blurry vision and dry eyes? My recent GI Mapping results show significant Microsporidia. (I have no idea why, unless it is because I have well water. None of the other causes are relevant.) I have asked several doctors about the intermittent blurry vision I have been experiencing for 7 years or so, and my recent Optometrist said I have severe dry-eye which is not improving with the use of Restasis for the past year. Thank you!

This episode answers questions related to dry eyes, glaucoma, improving nearsightedness, UV lights, and blurry vision. Question 1 0:39 - 8:53 I have some questions for you regarding my mom's eye issues.  She has had a cornea transplant in her left eye and is having issues with it. She is on two medications:  Simbrinza 1% and Systane (both eye drops are taken twice per day).  Her right eye is getting very dry. I bought her the MSM drops you offer on your website.  She is using them several times per day in her right eye but says they don't seem to be relieving the dryness. I tried to speak to her doctor about using them in both eyes but did not get a nice response. I now have my mom taking the oral MSM along with the eye drops but she keeps having issues. Question 2 8:54 - 12:59 What would you suggest if I'm already on medication for the beginnings of glaucoma? Should I use with or taper over to MSM? Please advise because I fear this medicine I'm using may be harmful. Thank you. Question 3 13:00 - 18:17 Many health gurus are adamant that sunglasses should never be worn especially ones with polarized lenses. I do sun exposure without sunglasses early and late in the day but find I am more comfortable with sunglasses in the middle of the day and when I drive. Is there a particular problem with polarized lenses? Question 4 18:18 - 25:51 Hey Dr. Berne! I'll get right to the point: my vision is terrible (6.5 in the left eye and 7.5 in the right eye) and I'm only 23.  I want to improve my vision, maybe even get it to 20/20 if that's possible. I want to downgrade the prescription of my glasses a bit, as you've advised, to get my eyes working more, but I'm currently dealing with posterior blepharitis in my left eye, so my vision's blurry in that eye. I know I can reduce the prescription for my right eye and be okay, but I am not sure what to do for the left eye since the vision's blurry regardless. I've been doing your dry eye exercises at least 1-2 times per day. Any tips on what I can do? Question 5 25:51 - 30:21 I had cataract surgery on both eyes in June. Apparently, both of the implanted lenses were cloudy on the back. I have to wait until November to have a laser treatment to clear that up. However, I have what appears to be “blinders” on the outside edge of my vision. I was told there is nothing that can be done about it and that is from the incision. I am told it should go away in time but no one knows how long. Is there anything I can do to help this heal/go away? Question 6 30:21 - 36:27 Have you heard of Microsporidia Fungus growth causing blurry vision and dry eyes? My recent GI Mapping results show significant Microsporidia. (I have no idea why, unless it is because I have well water. None of the other causes are relevant.) I have asked several doctors about the intermittent blurry vision I have been experiencing for 7 years or so, and my recent Optometrist said I have severe dry-eye which is not improving with the use of Restasis for the past year. Thank you!

This episode answers questions related to cataracts, glaucoma, dry-eye syndrome, recovering from cataract surgery, improving learning disabilities, and how to use pinhole glasses to improve vision. Question 1 2:57 - 11:50 How did you cure your learning disability holistically? Question 2 11:51 - 15:38 I have just been put on Restasis. Can I take MSM 15% drops also, at least 15 minutes apart? Question 3 15:39 - 19:44 I just watched your video on cataracts & other great informative videos...thanks!  What can patients do who have already had cataract surgery to nourish their eyes? Also, I now suffer from 'dry eye' and & have glaucoma in one eye......HELP! Question 4 19:44 - 20:47 Is it safe to use MSM eye drops in an eye that has had cataract surgery? Question 5 20:47 - 24:07 Six years ago I had an eye aneurysm. My retina was not damaged but I still have a lot of blood debris/floaters. I was offered to go through a procedure to remove the vitreous of my left eye and replace it with some liquid. I don't know the name of this procedure. To be honest I am not thrilled about that. Could you please give me some input on my condition? Thank you very much. Question 6 24:07 - 28:05 I bought a pair of pinhole glasses. I remember seeing a podcast or a YouTube video where you explained how to use pinhole glasses, could you discuss and elaborate?

This episode answers questions related to cataracts, glaucoma, dry-eye syndrome, recovering from cataract surgery, improving learning disabilities, and how to use pinhole glasses to improve vision. Question 1 2:57 - 11:50 How did you cure your learning disability holistically? Question 2 11:51 - 15:38 I have just been put on Restasis. Can I take MSM 15% drops also, at least 15 minutes apart? Question 3 15:39 - 19:44 I just watched your video on cataracts & other great informative videos...thanks!  What can patients do who have already had cataract surgery to nourish their eyes? Also, I now suffer from 'dry eye' and & have glaucoma in one eye......HELP! Question 4 19:44 - 20:47 Is it safe to use MSM eye drops in an eye that has had cataract surgery? Question 5 20:47 - 24:07 Six years ago I had an eye aneurysm. My retina was not damaged but I still have a lot of blood debris/floaters. I was offered to go through a procedure to remove the vitreous of my left eye and replace it with some liquid. I don't know the name of this procedure. To be honest I am not thrilled about that. Could you please give me some input on my condition? Thank you very much. Question 6 24:07 - 28:05 I bought a pair of pinhole glasses. I remember seeing a podcast or a YouTube video where you explained how to use pinhole glasses, could you discuss and elaborate?

In Episode 5, Darrell White, MD, shares his thoughts on why every ophthalmologist in every subspecialty should be aware of the prevalence of dry eye and its impact on eye care. Everyone – including retina specialists need to be aware of dry eye :58 Financial disclosures 1:10 The hot dot in eye care 1:40 The space is growing: More people have dry eye and it’s affecting more of their lives 2:31 Dry eye and presbyopia-correcting IOLs 3:17 White’s personal dry eye story 4:54 Starting a dry eye practice from scratch 7:37 The archetypal patient defined in market research done by Allergan 8:12 The 3-generation decision maker on medical care for the family 9:10 Going from 0 patients on day 1, to more than 5,000 active patients in the first year 11:08 What has changed since then 11:52 Multi-screen lifestyle increasing dry eye population 12:05 The biggest symptom is blurry vision 13:34 The Linda Blair dry eye patient 14:41 Listen to your patient 15:56 Treating meibomian gland disease Diagnosing dry eye 17:50 Treating the dry eye patient 18:51 Artificial tears 19:00 Hypotonic tears 19:30 Restasis and Xiidra 20:56

Brad Moss, a partner at Mark Zaid Plc., discusses special counsel Robert Mueller's accusations against former Trump campaign chairman Paul Manafort for threatening witnesses. Plus, Shubha Ghosh, director the Syracuse University Intellectual Property law Institute, discusses Allergan's efforts to transfer the patent for the blockbuster dry-eye drug Restasis to a Native American tribe in a case that could forever change how the U.S. government reviews patents.  They speak with Bloomberg's June Grasso.  Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Brad Moss, a partner at Mark Zaid Plc., discusses special counsel Robert Mueller’s accusations against former Trump campaign chairman Paul Manafort for threatening witnesses. Plus, Shubha Ghosh, director the Syracuse University Intellectual Property law Institute, discusses Allergan’s efforts to transfer the patent for the blockbuster dry-eye drug Restasis to a Native American tribe in a case that could forever change how the U.S. government reviews patents.  They speak with Bloomberg’s June Grasso. 

We discuss a tweet and a paper claiming that pharmaceutical companies don’t even need to produce effective drugs anymore.  All they need is “an effective marketing campaign” and billions of dollars in annual sales soon follow.  This is a very dubious claim on the face of it, but Anish did some investigating of his own. LINKS: Schwartz, LM, and Woloshin, S.  https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2666792?redirect=true (A Clear-Eyed View of Restasis and Chronic Dry Eye Disease) WATCH ON YOUTUBE: https://youtu.be/tF6LWLPd3qc (Watch the episode) on our YouTube channel Support this podcast

The courts and Congress have long acknowledged the sovereign status of Native American tribes. Tribes, like states and related instrumentalities such as public universities, may invoke sovereign immunity to avoid being hauled into federal court and other legal proceedings. A new and unlikely twist brings tribal immunity to the most unlikely of forums for the latest battle, the Patent Trial and Appeal Board. This teleforum will explore the growing and hotly contested trend of Native American tribes as patent owners and debate the arguments for and against tribal immunity. In 2017, Allergan assigned a portfolio of patents for it popular Restasis eye drops to the St. Regis Mohawk. At the time, the patents were the subject of district court litigation Allergan brought against several generic drug companies that had filed Abbreviated New Drug Applications. At the same time, the ANDA filers petitioned the PTAB to revoke Allergan’s patents. After trial but before final judgment, Allergan assigned its patents to the Mohawk tribe. The tribe moved to terminate the Inter Partes Review (IPR) proceedings at the PTAB. What has followed has been months of briefing that has drawn extraordinary attention, including numerous amicus briefs, to the PTAB. Featuring:Prof. Gregory Ablavsky, Stanford Law SchoolMr. Aaron Cooper, Vice President, Global Policy, BSA | The Software AllianceMr. Michael Shore, Partner, Shore Chan Depumpo LLCModerator: Mr. Brian Pandya, Partner, Wiley Rein LLP Teleforum calls are open to all dues paying members of the Federalist Society. To become a member, sign up here. As a member, you should receive email announcements of upcoming Teleforum calls which contain the conference call phone number. If you are not receiving those email announcements, please contact us at 202-822-8138.

The courts and Congress have long acknowledged the sovereign status of Native American tribes. Tribes, like states and related instrumentalities such as public universities, may invoke sovereign immunity to avoid being hauled into federal court and other legal proceedings. A new and unlikely twist brings tribal immunity to the most unlikely of forums for the latest battle, the Patent Trial and Appeal Board. This teleforum will explore the growing and hotly contested trend of Native American tribes as patent owners and debate the arguments for and against tribal immunity. In 2017, Allergan assigned a portfolio of patents for it popular Restasis eye drops to the St. Regis Mohawk. At the time, the patents were the subject of district court litigation Allergan brought against several generic drug companies that had filed Abbreviated New Drug Applications. At the same time, the ANDA filers petitioned the PTAB to revoke Allergan’s patents. After trial but before final judgment, Allergan assigned its patents to the Mohawk tribe. The tribe moved to terminate the Inter Partes Review (IPR) proceedings at the PTAB. What has followed has been months of briefing that has drawn extraordinary attention, including numerous amicus briefs, to the PTAB. Featuring:Prof. Gregory Ablavsky, Stanford Law SchoolMr. Aaron Cooper, Vice President, Global Policy, BSA | The Software AllianceMr. Michael Shore, Partner, Shore Chan Depumpo LLCModerator: Mr. Brian Pandya, Partner, Wiley Rein LLP Teleforum calls are open to all dues paying members of the Federalist Society. To become a member, sign up here. As a member, you should receive email announcements of upcoming Teleforum calls which contain the conference call phone number. If you are not receiving those email announcements, please contact us at 202-822-8138.

Brent Saunders, president, CEO, and chairman of global leader Allergan, sits down at OIS@AAO to discuss what impact the pending loss of the Restasis patent could have on the company. He also rejects talk of Allergan breaking off its ophthalmology business, saying the company is in the sector to stay.

Today's rapid-response episode begins with an update on the Allergan patent licensing scheme discussed in Episode 107.  What does a federal judge think of this One Weird Trick to avoid certain legal proceedings?  Listen and find out! Next, our main segment looks at Donald Trump's efforts to undermine Obamacare from the Oval Office.  Does this violate the Constitution?  Is there anything we can do about it?  The answer might surprise you! After that, we continue the theme by looking at the two recent injunctions handed down by U.S. District Courts in Hawaii and Maryland regarding the third iteration of President Trump's Travel Ban. Finally, we end with a new Thomas Takes the Bar Exam Question #46 about prenuptial agreements.  Remember that you can play along with #TTTBE by retweeting our episode on Twitter or sharing it on Facebook along with your guess.  We'll release the answer on next Tuesday's episode along with our favorite entry! Recent Appearances Thomas was on Episode 60 of the "Atheists on High" podcast; give it a listen! Show Notes & Links We first discussed the Allergan patents for Restasis back in Episode 107, along with no other controversial things at all. The court's opinion regarding Allergan's joinder of the native American tribe can be found here; and the main opinion on the validity of the patent can be found here. This is a link to the Vox article by Prof. Gluck alleging that Trump has violated the "Take Care" clause of the Constitution. The Nixon-era case we discuss is Train v. City of New York, 420 U.S. 35 (1975). This is the text of Presidential Proclamation 9645 ("EO-3"). Here is a link to the Hawaii opinion; and here is a link to the Maryland opinion. Support us on Patreon at:  patreon.com/law Follow us on Twitter:  @Openargs Facebook:  https://www.facebook.com/openargs/ And email us at openarguments@gmail.com  

Check in with Brad Sheafe, Chief Intellectual Property Officer (CIPO) and David Pridham, CEO of Dominion Harbor, respectively as they weigh in on the latest IP protection strategy in assigning one’s patent rights to legally protected sovereign entities in a last ditch effort to protect one’s patent rights from the Patent Trial and Appeals Board (PTAB). Specifically, they are directing their attention to the recent Allergan case where they have agreed to pay the St. Regis Mohawk upwards of $15M a year to maintain ownership of their Restasis drug patents in an effort to exclude their scrutiny of both the Federal court system and the PTAB simultaneously. Panel stacking – assigning specific Judges to specific cases in an effort predict or affect a particular outcome. Worse, the USPTO has gone on congressional record admitting to as much with not a hint of remorse or collusion guilt. PTAB – is not an Article III tribunal however it acts as one on ruling over private property issues e.g. Patents

Dry eyes affect 25 million people in the United States and you could very well be one of them! There are many over-the-counter eye drops and artificial tears on the market as well as one which can be prescribed by your optometrist called Restasis. Learn from Carol Johnson, OD about how to identify dry eye syndrome and ways to create relief.